INTRODUCTION
Mutations of the Aristaless-related homeobox (ARX) gene (OMIM *300382) cause a variety of neurological disorders including infantile spasms with or without dystonia or other movement disorders, with or without cerebral malformations [Kato et al., 2004; Guerrini et al., 2007; Poirier et al., 2008] . The genotype-phenotype correlation seems to indicate that malformation phenotypes are caused by protein truncation mutations and missense mutations in the homeobox, whereas nonmalformation phenotypes are associated with missense mutations outside the homeobox and with polyalanine tract expansion .
Expansions of the first polyalanine tract of the ARX gene are associated with X-linked infantile spasm syndrome and epileptic dyskinetic encephalopathy [Stromme et al., 2002; Turner et al., 2002; Kato and Dobyns, 2005; Guerrini et al., 2007] . Longer expansions of the same polyalanine tract have been recently reported as a cause of early infantile epileptic encephalopathy with suppression burst pattern (Ohtahara syndrome; OS) without brain malformations and a possible relationship between the length of this repeat region and the severity of the epileptic phenotype has been suggested [Kato et al., 2003 .
To further support the possible causative relationship between ARX gene mutations and OS, we report two related male individuals with OS that evolved into West syndrome phenotype and subsequently into an epileptic encephalopathy with polymorphic and refractory seizures, who carry a previously unreported missense mutations in exon five of ARX gene.
CLINICAL REPORTS
The two boys we report on were born to two monozygotic twin sisters and both had a neonatal-onset encephalopathy. A maternal uncle, who died at 2 years of age during a prolonged status epilepticus was reported as affected by neonatal-onset spasms and successive refractory focal seizures (Fig. 1 ).
Patient 1
Patient 1 was the first child of healthy unrelated parents, born at term, after an uneventful pregnancy and vacuum-assisted delivery. At birth weight was 2,380 g (<3rd centile), length was 47 cm (3rd centile), and head circumference was 31 cm (2nd centile). At age 20 days, especially at drowsiness, he presented clusters of spasms associated with erratic myoclonic jerks.
The EEG disclosed a suppression burst pattern compatible with OS (Fig. 2) . Adrenocorticotropic hormone and vigabatrin were not effective. After the introduction of valproate, spasm frequency decreased but the EEG became hypsarrhythmic.
The growth parameters remained low during his development: at 6 months head circumference was 41 cm (2nd centile), weight 6,500 g (3rd centile), and length 63 cm (3rd centile); at 12 months head circumference was 42 cm (<2nd centile), weight 9,300 g (10th centile), and length 72 cm (3rd centile) and now (22 months of age) he showed microcephaly (head circumference 42 cm, <2nd centile) and growth deficiency (weight 10,000 g, <3rd centile, length 85 cm, 25th centile) without dysmorphic features, intellectual impairment, hypotonic tetraparesis with pyramidal signs, and requires gavage feeding. Physical examination did not reveal any genital anomaly and now penile stretched length is 3.5 cm (10-50th centile). Daily isolated spasms and focal seizures persist despite the therapy; the EEG is characterized by multifocal paroxysms. Metabolic tests [very long chain fatty acids (VLCFA), plasma and urinary aminoacids, carnitine, and acilcarnitine] showed normal results. Brain MRI performed at 6 months of age was normal, while at 22 months it showed diffuse brain atrophy. Standard karyotype and analysis of telomeric rearrangements were both normal. Patient 2 was the second child of nonconsanguineous parents. The father had benign childhood epilepsy. Pregnancy, delivery, weight (3,200 g), length (51 cm), and head circumference (33 cm) at birth were normal. Focal seizures, characterized by staring followed by right-side jerks and brief generalized clonic attacks, occurred at 6 days of life. EEG showed a suppression-burst pattern that was compatible with OS ( Fig. 3) . Vitamin B6, phenobarbital, and midazolam were used without success. At age 2 months, he presented with polymorphic focal motor seizures associated with spasms in clusters evolving into epileptic encephalopathy resistant to vigabatrin, phenytoin, adrenocorticotropic hormone. The EEG became hypsarrhythmic. Other treatments (lamotrigine, carbamazepine, clobazam, and valproate) did not change seizurefrequency. Postnatal development was within normal ranges since the age of 22 months, when he showed progressive deceleration of head circumference (46.5 cm, 50th-2nd centile). At the age of 2 years, he had microcephaly (head circumference 46.5 cm,<2nd centile; weight 10,400 g, 10th centile; length 87 cm, 50th centile) without dysmorphic features, intellectual impairment, and spastic tetraparesis requiring gavage feeding. No genital anomalies were found and penile stretched length was 4 cm (50th centile) at the age of 2 years. Results of several investigations (blood lactate and ammonium, plasma aminoacids, VLCFA, serum sialotransferrin isofocusing, purines and pyrimidines, sulfi-test, serum copper and ceruloplasmin, CSF analysis and dosage of neurotransmitters, urinary excretion of organic acids and aminoacids) were negative. Brain MRI at age 6 days was normal, and consecutive MRI at age 2 years revealed a slight diffuse brain atrophy. Standard karyotype was normal.
Molecular analysis
Regular informed consent for genetic testing was obtained from the parents of the two affected boys. Genomic DNA was extracted from peripheral blood leukocytes (PBL) with standard methods. Mutation analysis of the ARX gene was performed by PCR amplification and direct sequencing of fragments representing all the coding exons and intron-exon boundaries, with primers and conditions modified by Kato et al. [2004] . Direct sequencing of the amplification products was performed with the use of the BigDye Ò Terminator v3.1 Cycle Sequencing Kit (PE Applied Biosystems, Foster City, CA) on an ABI 3100 automated DNA sequencer (Applied Biosystems). The sequences obtained were compared with the reference ARX sequence (GenBank accession number: NM_139058) by BLAST analysis. Total RNA was extracted from fresh peripheral blood using the Trizol procedure (Life Technologies, Grand Island, NY) and cDNA was obtained using the superscript first-strand system for RT-PCR, with the primers being selected by Primer Express software. Primers amplifying a product from exon 4 to exon 5, fw: 5'-CCAGCTTT-CATCAGCCCGGC-3' and rev: 5'-GTGCTGGTGCCCGGCAGG-3' were designed for the missense mutation.
RESULTS
The mutation scanning performed allowed us to detect, in both individuals, the presence of a single base substitution at nucleotide 1604 of the ARX gene coding sequence (c.1604T>A: Ref. Seq. NM_139058), resulting in the substitution of the leucine residue at position 535 of the aminoacid sequence with a glutamine (p.Leu535Gln). The substitution has not been found in 150 X chromosomes from the control population. The same mutation was present in the DNA of the two mothers, and maternal grandmother, while it was absent in the two unaffected maternal uncles. Moreover, linkage analysis (data not shown) with a panel of microsatellites, spanning the whole X chromosome excluded the disease causing involvement of other X chromosome loci. RT-PCR analysis evidenced the transcription of the mutant allele.
DISCUSSION
Both children presented with specific electroclinical features suggestive of OS subsequently evolving into a drug-resistant epileptic encephalopathy with spasms. The X-linked inheritance, suggested by the family history, is confirmed by the molecular results.
Besides both children show a clinical phenotype characterized by microcephaly without dysmorphic features and absence of genital anomalies, although patient one presented growth deficiency from birth, while Patient 2 showed normal auxological measures at birth and developed progressive microcephaly in the second year of life.
In both cases diffuse brain atrophy on MRI at 2 years of age could be related to the persistence of severe epileptic encephalopathy.
The electroclinical features of our subjects, except for the absence of genitalia malformations, are similar to those reported by Kato et al. [2007] . Recently, a novel ARX gene mutation in male infant without genital anomalies, presenting with OS associated with a rapidly progressive and severe neurodegeneration with cortical atrophy, has been described [Absoud et al., 2010] .
This confirms the possible causative relationship between ARX gene mutations and OS. The molecular analysis of the ARX gene revealed a missense mutation (c.1604T>A) on the DNA of both affected boys, of their mothers and grand mother. This previously unreported mutation, not found in more than 100 X chromosomes of the general population, is to be considered pathogenic. In fact it leads to a variation of the chemical characteristics of the aminoacid sequence by substituting the nonpolar hydrophobic leucine residue with a polar hydrophilic glutamine in the functionally relevant Aristaless domain (p.Leu535Gln) of the gene.
To further confirm the disease-causing nature of the detected variant, a multi-sequence alignment analysis was performed that showed a strong phylogenetic conservation of the specific leucine residue. The translation of the aberrant allele, as demonstrated by the cDNA analysis, excluded the occurrence of a nonsense mediated RNA decay suggesting that the presence of an aberrant protein, rather than its absence, is responsible for the disease. The absence of the mutation in the unaffected uncles further supports the segregation of the molecular defect with the disease.
Differently from sporadic OS cases Absoud et al., 2010] , the novel mutation of the ARX gene we describe is found to segregate in a family, and consists in a missense mutation rather than in a longer expansion of the first polyalanine tract of the gene.
The similar clinical phenotypes, characterized by microcephaly without dysmorphic features and absence of genital anomalies, and electroclinical picture, suggestive of OS, presented in the patients we report on are important to better define the phenotype related to this novel ARX gene mutation and to confirm the differentiation between a malformative and nonmalformative group, related to missense mutations outside the homeobox of the gene.
This report demonstrates the involvement of ARX gene mutations other than longer polyalanine tract expansions, in the pathogenesis of cryptogenic epileptic encephalopathy with very early onset, such as OS. Our data suggests that the severity of the electroclinical picture (OS vs. West syndrome) in patients with ARX mutations does not simply, or exclusively, correlate with the extent of expansions of the polyalanine tracts, but rather with the functional effect of different pathogenetic mutations.
Furthermore, while supporting the causative relationship between ARX mutations and OS, our data strongly suggests the opportunity for searching for ARX mutations in patients with sporadic or familial OS.
